Market Entry Blocked

by impurity control

Semaglutide has 24 known impurities that need to be managed to reach the FDA specification. Failure to do so, drives up your cost and prevents you from entering the market.

GLP-1 Technology's process to manufacture GLP-1 drugs mitigates the impurity generation & decreases the impurity burden by 70%

The GLP-1 Technology "Secret"

Junior Employee doubled production output and increased crude batch purity of GLP-1 drug by 40% in 1 month

24 hurdles to access $200B market

Small fragments and a bespoke biocatalyst (Enzyme)

Building complex GLP-1 drugs via small fragments

"Drop In Solution" without the need to expand their team

Go to our LinkedIn page to download the latest White Papers

No Capex Expansion, standard reactors worked!

Explore how GLP-1 Technology can help position you in the market & current products we have available

"Simple in theory but complex in execution", the market told us.

At GLP-1 Technology we applied over 20 years of experience to develop a biocatalyst that unlocks the fragment approach.

Not only do enzyme discriminate impurities, now, you can also increase your batch output by 4 fold and decrease your COGS by 60-80%!

Why is the industry adopting the GLP-1 Technology solution?

Clients Experiences